Madrid, Oct 15 (EFE) .- The Spanish biotechnology company PharmaMar announced this Thursday the extension to Canada of the agreement it signed in 2019 with the Irish company Jazz Pharmaceuticals to distribute lurbinectedin in the US, which is used in the treatment of small cell lung cancer metastatic.
In a note sent to the Spanish market supervisor, the CNMV, PharmaMar explains that it will receive up to 5 million dollars (4.3 million euros) between the initial payment and the payments for regulatory milestones in Canada.
In addition, you will have the rights generated by the sale of the product.
The Spanish company will retain the production rights for lurbinectedin and will supply the product to Jazz Pharmaceuticals.
PharmaMar may also receive tiered “royalties” on future net sales of lurbinectedin in Canada, and may also receive up to an additional $ 3 million as potential milestone payments.
The terms of the license agreement signed in December 2019 regarding the exclusive license granted to Jazz in the United States (including Jazz’s payment obligations) remain unchanged, the note explains.
Zepzelca ™ (lurbinectedin) was approved by the FDA in the United States for the treatment of metastatic small cell lung cancer on June 15, 2020, and the application for registration under accelerated approval regulation has been submitted to Australian health agencies , Switzerland, Israel and Singapore.
(c) EFE Agency